These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310 [TBL] [Abstract][Full Text] [Related]
25. Papillomavirus-like particles and HPV vaccine development. Schiller JT; Lowy DR Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529 [TBL] [Abstract][Full Text] [Related]
26. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Stanley M; Lowy DR; Frazer I Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996 [TBL] [Abstract][Full Text] [Related]
27. [Vaccination against human papillomavirus and against the cellular proliferation that it induces: facts and expectations]. Giannouli C; Burny A; Hallez S J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):258-60. PubMed ID: 10804365 [TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Tomson TT; Roden RB; Wu TC Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945 [TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus vaccines. Stanley MA Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836 [TBL] [Abstract][Full Text] [Related]
30. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932 [TBL] [Abstract][Full Text] [Related]
31. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Chen J; Ni G; Liu XS Cell Immunol; 2011; 269(1):5-9. PubMed ID: 21477796 [TBL] [Abstract][Full Text] [Related]
33. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842 [TBL] [Abstract][Full Text] [Related]
34. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. Nieland JD; Da Silva DM; Velders MP; de Visser KE; Schiller JT; Müller M; Kast WM J Cell Biochem; 1999 May; 73(2):145-52. PubMed ID: 10227378 [TBL] [Abstract][Full Text] [Related]
35. [Recombinant therapeutic vaccines against cancer of the uterine cervix]. Berumen J; Villegas N Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250 [TBL] [Abstract][Full Text] [Related]
36. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500 [TBL] [Abstract][Full Text] [Related]
37. HPV vaccines. Stanley M Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):279-93. PubMed ID: 16356772 [TBL] [Abstract][Full Text] [Related]
38. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. Stern PL J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015 [TBL] [Abstract][Full Text] [Related]
39. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Ault KA Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901 [TBL] [Abstract][Full Text] [Related]